Mitchell Nagao, PharmD, MBA

SVP, Medical Affairs
Soleno Therapeutics

Poster(s):

• (147) Expected vs observed mortality rates, expressed as number needed to treat, from a Phase 3 clinical trial program of patients with hyperphagia and Prader-Willi Syndrome treated with diazoxide choline extended release (DCCR)
  Wednesday, October 29, 2025

• (148) The burden of Prader-Willi Syndrome on patients and the healthcare system: a cross-sectional examination of emergency department visits and inpatient stays in US claims
  Wednesday, October 29, 2025